FDA 'Evolving' Homeopathic Drug Enforcement With Risk-Based Approach

Problems stated in a draft guidance where FDA will "prioritize enforcement and regulatory actions" includes products with routes of administration other than oral and topical or intended to be used for the prevention or treatment of serious or life-threatening diseases and conditions.

FDA will put more teeth into its homeopathic drug industry oversight under a draft guidance that identifies problems it will target for enforcement while allowing the products to remain available without pre-market approval.

The draft guidance published Dec. 18 states that FDA will use an enforcement approach similar to its oversight...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation

Cosmetics Europe Pushes Commission To Lower Industry’s UWWTD Costs

 
• By 

The European Commission plans to conduct an updated study that could reallocate extended producer responsibility costs under its Urban Wastewater Treatment Directive, a step welcomed by industry after an analysis concludes the directive vastly overestimates cosmetics’ contribution to toxic waste.

‘Off-Label’ Beauty Hacks: Navigating the Risks of Consumer-Driven Innovation

 
• By 

Guest authors Rachel Raphael, partner at Morgan, Lewis & Bockius, LLP and associates at the firm, Elizabeth Bresnahan and Kathryn Ignash, advise beauty companies on how to navigate the legal risks associated with consumers ‘off-label’ beauty hacks.

MoCRA Implementation Delay Creates More Legal Exposure For Stakeholders – Attorney

 

The delay in implementation of MoCRA is seen by many companies as a temporary reprieve, but it does create more legal uncertainty, says attorney Marissa Alkhazov of law firm Buchalter.